4
MARKET OVERVIEW
Highlights the market structure, growth drivers, restraints, and near-term inflection points influencing performance.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Presents a concise view of industry direction, strategic priorities, and key indicators influencing market momentum.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITION RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN NORTH AMERICA HEALTHCARE INDUSTRY
5.2.4
TRENDS IN NORTH AMERICA PHARMA INDUSTRY
5.5.1
AVERAGE SELLING PRICE OF KEY PLAYERS, BY END-USE INDUSTRY,
5.5.2
AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022-2024
5.5.3
AVERAGE SELLING PRICE TREND, BY COUNTRY, 2022-2024
5.6
KEY CONFERENCES & EVENTS, 2025-2026
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.7.1
DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
5.8
INVESTMENT AND FUNDING SCENARIO
5.10
IMPACT OF 2025 US TARIFF ON NORTH AMERICA HUMAN MICROBIOME MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1.1
WHOLE-GENOME SEQUENCING
6.1.2
16S RNA SEQUENCING METHOD
6.1.3
NANOPORE SEQUENCING
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
METATRANSCRIPTOMICS
6.3
ADJACENT TECHNOLOGIES
6.7
IMPACT OF AI/ GEN AI ON NORTH AMERICA HUMAN MICROBIOME MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN AI-ENABLED HUMAN MICROBIOME WORKFLOWS
6.7.3
CASE STUDIES OF AI ADOPTION
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED MICROBIOME ANALYTICS SOLUTIONS
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2
DECISION-MAKING PROCESS
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
NORTH AMERICA HUMAN MICROBIOME MARKET, BY PRODUCT, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
9.2
HUMAN MICROBIOME DRUGS
9.3
HUMAN MICROBIOME SUPPLEMENTS
9.4
MICROBIOME DIAGNOSTICS
10
NORTH AMERICA HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
10.2
BACTERIAL CONSORTIA TRANSPLANT (BCT)/FECAL MICROBIOTA TRANSPLANT (FMT)
10.3
LIVE BACTERIA PRODUCTS
11
NORTH AMERICA HUMAN MICROBIOME MARKET, BY DISEASE, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
11.3
GASTROINTESTINAL DISEASES
11.4
ENDOCRINE & METABOLIC DISORDERS
12
NORTH AMERICA HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
12.2
ORAL ROUTE OF ADMINISTRATION
12.3
RECTAL ROUTE OF ADMINISTRATION
13
NORTH AMERICA HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
13.2
STRAIN DEVELOPMENT & OPTIMIZATION
13.3
FERMENTATION & DOWNSTREAM PROCESSING
13.4
FORMULATION & FILL/FINISH
14
NORTH AMERICA HUMAN MICROBIOME MARKET, BY END USER, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
14.3
LONG-TERM CARE FACILITIES
15
NORTH AMERICA HUMAN MICROBIOME MARKET, BY COUNTRY, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
16.2
KEY PLAYERS’ STRATEGIES/RIGHT TO WIN (JANUARY 2022 – NOVEMBER 2025)
16.3
REVENUE ANALYSIS, 2020-2024
16.4
MARKET SHARE ANALYSIS,
16.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
16.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.5.5.1
COMPANY FOOTPRINT
16.5.5.2
COUNTRY FOOTPRINT
16.5.5.3
PRODUCT FOOTPRINT
16.5.5.5
DISEASE FOOTPRINT
16.6
COMPANY EVALUATION MATRIX: START-UPS/SMES,
16.6.1
PROGRESSIVE COMPANIES
16.6.2
RESPONSIVE COMPANIES
16.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
16.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
16.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
16.7
COMPETITIVE SCENARIO
16.7.1
PRODUCT/SERVICE LAUNCHES
16.8.1
INTERNATIONAL FLAVOURS & FRAGRANCES INC.
16.8.3
SERES THERAPEUTICS
16.9
COMPANY VALUATION AND FINANCIAL METRICS
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE NORTH AMERICA HUMAN MICROBIOME MARKET LANDSCAPE
17.1.1
INTERNATIONAL FLAVORS & FRAGRANCES INC.
17.1.1.1
BUSINESS OVERVIEW
17.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.1.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.1.3.2
STRATEGIC CHOICES
17.1.1.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.2.1
BUSINESS OVERVIEW
17.1.2.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.2.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.2.3.2
STRATEGIC CHOICES
17.1.2.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.3
SERES THERAPEUTICS
17.1.3.1
BUSINESS OVERVIEW
17.1.3.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.3.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.3.3.2
STRATEGIC CHOICES
17.1.3.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.4
BIOHM TECHNOLOGIES
17.1.4.1
BUSINESS OVERVIEW
17.1.4.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.4.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.4.3.2
STRATEGIC CHOICES
17.1.4.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.5.1
BUSINESS OVERVIEW
17.1.5.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.5.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.5.3.2
STRATEGIC CHOICES
17.1.5.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.6.1
BUSINESS OVERVIEW
17.1.6.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.6.3
RECENT DEVELOPMENTS
17.1.7
INFINANT HEALTH INC.
17.1.7.1
BUSINESS OVERVIEW
17.1.7.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.7.3
RECENT DEVELOPMENTS
17.1.8
FINCH THERAPEUTICS GROUP, INC.
17.1.8.1
BUSINESS OVERVIEW
17.1.8.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.8.3
RECENT DEVELOPMENTS
17.1.9.1
BUSINESS OVERVIEW
17.1.9.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.9.3
RECENT DEVELOPMENTS
18.1.1.1
KEY SOURCES OF SECONDARY DATA
18.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
18.1.2.1
BREAKDOWN OF PRIMARIES
18.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
18.2
MARKET SIZE ESTIMATION
18.2.1
NORTH AMERICA HUMAN MICROBIOME MARKET SIZE ESTIMATION,
18.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
18.2.1.2
MNM REPOSITORY ANALYSIS
18.2.1.3
SECONDARY ANALYSIS
18.2.1.4
PRIMARY RESEARCH
18.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
18.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
18.3
MARKET GROWTH RATE PROJECTIONS
18.6
RESEARCH LIMITATIONS & RISK ASSESSMENT
19.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
AVAILABLE CUSTOMIZATIONS
Growth opportunities and latent adjacency in North America Human Microbiome Market